Guidelines on HER2 testing in patients with invasive breast cancer by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have been updated for the first time since their publication in 2007. The guidelines recommend HER2 testing for all newly diagnosed breast cancer patients with either early-stage invasive or metastatic disease. The new update is based on a new review of the literature. Read more here.
Published guidelines: Wolff AC, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Oct 7. [Epub ahead of print] PMID: 24101045
No comments:
Post a Comment